A phase II study of cisplatin therapy in recurrent childhood brain tumors. A report from the Childrens Cancer Study Group.
Thirty-six children with brain tumors were treated with surgery, radiation and/or adjuvant chemotherapy. After tumor recurrence, cisplatin (60 mg/m2/day IV X 2) was given every three to four weeks. CT scans were used to measure drug response prior to the first, third and fifth courses. Complete and partial responses were demonstrated in nine of 31 evaluable patients. Dose limiting toxicities were renal and auditory. Seven patients developed the syndrome of inappropriate antidiuretic hormone secretion. This study confirms that cisplatin is active in a spectrum of brain tumors.
University of Louisville.
S J
SJ
Bertolone
E S
ES
Baum
W
W
Krivit
G D
GD
Hammond
D000293:Adolescent; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000556:secondary; D002648:Child; D002675:Child, Preschool; D002945:Cisplatin / Q000627:therapeutic use* / Q000633:toxicity; D004806:Ependymoma / Q000188:drug therapy* / Q000556:secondary; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008527:Medulloblastoma / Q000188:drug therapy* / Q000556:secondary; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*
D002945:Cisplatin